Clinical characteristics and survival of patients with pulmonary veno-occlusive disease.
- Author:
Xin JIANG
1
;
Fa-dong CHEN
;
Jing HE
;
Rong JIANG
;
Ruo-min DI
;
Qin-hua ZHAO
;
Zhi-cheng JING
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Cardiac Catheterization; China; Diagnostic Errors; Familial Primary Pulmonary Hypertension; pathology; therapy; Female; Hemodynamics; Humans; Lung; Lung Transplantation; Male; Pulmonary Veno-Occlusive Disease; diagnosis; pathology; therapy; Retrospective Studies; Tomography, X-Ray Computed; Young Adult
- From: Chinese Journal of Cardiology 2011;39(10):896-900
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical presentation, diagnosis, treatment and outcome of patients with pulmonary veno-occlusive disease (PVOD).
METHODSData from patients diagnosed as PVOD from May 2008 to May 2011 in Shanghai Pulmonary Hospital, Tongji University were retrospectively reviewed.
RESULTSDuring this period, 5 patients [4 female, aged from 12 to 42 (22 ± 12) years old] were diagnosed as PVOD. The durations from symptoms onset to PVOD diagnosis was 2 to 50 (16 ± 20) months and four of them were previously diagnosed as idiopathic pulmonary arterial hypertension. All patients at the time of PVOD diagnosis had a severely impaired WHO pulmonary hypertension functional class (3 in class III and 2 in class IV). Furthermore, all patients characterized by a typical sign of centrilobular ground-glass opacities in high-resolution computed tomography, a markedly reduction of diffusing capacity of the lung for carbon monoxide [(38 ± 12)% of predicted value] in pulmonary functional test and severely compromised cardio-pulmonary hemodynamics identified by right heart catheterization. All patients received conventional and pulmonary arterial hypertension specific therapies, and then followed-up regularly. Up to now, 4 out of 5 patients died due to refractory right heart failure. The durations from symptoms onset to death and from PVOD establish to death were 5 - 65 (27 ± 26) months and 1 - 16 (9 ± 9) months, respectively.
CONCLUSIONSPVOD is a rare and malignant cardio-pulmonary disorder that often be misdiagnosed as idiopathic pulmonary arterial hypertension. Given the poor responses to modern pulmonary arterial hypertension specific therapies, lung transplantation remains the treatment of choice.